Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)

Canadian Journal of Cardiology

Volumn 13, Issue 6, 1997, Pages 591-599

  Teo, Koon K ^a   Burton, Jeffrey R ^b   Buller, Christopher ^b   Plante, Sylvain ^b   Yokoyama, Shinji ^b   Montague, Terrence J ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

Angiotensin converting enzyme inhibitors; Coronary atherosclerosis; Factorial design; HMG CoA reductase inhibitors; Quantitative coronary angiography; Regression

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HUMANS; LOVASTATIN; MALE; MIDDLE AGED; RESEARCH DESIGN; SIMVASTATIN; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0030809424     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. Am J Cardiol 1976,37:269-82.
2. Keys A. Seven Countries. A Multivariate Analysis of Health and Coronary Heart Disease. Cambridge: Harvard University Press, 1980.
3. Stamler J, Wentworth D, Neaton J, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screens of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986,256:2823-8.
4. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 vears for participants in the Multiple Risk Factor Interventional Trial: findings related to a prior hypothesis of the trial. JAMA 1990,263:1795-801
5. Neaton JD, Blackburn H, Jacobs D, et al. Multiple Risk Factor Intervention Trial Research Group: serum cholesterol level and mortality findings tor men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992,152:1490-500.
6. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol and coronary heart disease in population with low cholesterol BMJ 1991,303:276-82.
7. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease to older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992,2:161-6.
8. Montague T, Tsuvuki R, Burton J, Williams R, Dzavik V, Teo K. Prevention and regression of coronarv, atherosclerosis Is it safe and etticaclous therapy' Chest 1994;105-718-26.
9. Warers D. Higginson L, Gladstone P, et al Effects of monotherapy with an HMG CoA reductase inhibitor on the progression of coronarv atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
10. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
11. Dayton S, Pearce ML, Hashloto S, Dixon WJ, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969;39-40(Suppl 2):169.
12. Hjermann I, Holme I, Byre KV, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981;248:1465-77.
13. Frick ME, Elo O, Haapa MH, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes of risk factors and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
14. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
15. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.
16. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990;301:309-14.
17. Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304:431-4.
18. Jacobs D, Blackburn H, Higgins M, et al, for Participants in the Conference on Low Cholesterol: Mortality associations. Report on the conference on low cholesterol: mortality associations. Circulation 1992;86:1046-60.
19. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease: II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-66.
20. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
21. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
22. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 1997;336:153-62.
23. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
24. Hlatky MA, Hulley SB. Plasma cholesterol: can it be too low? Arch Intern Med 1981;141:1132.
25. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
26. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
27. Zhao XQ, Brown BG, Hillger L, et al. Effects of intensive lipid lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Circulation 1993;88:2744-53.
28. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:293-302.
29. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
30. Lonn E, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
31. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990;264:3013-7.
32. Buchwald H, Varco R, Matts JP, et al, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55.
33. Brown BG, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
34. Watts GF, Lewis B, Brunt JNH, et al. Effect of coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
35. Waters D, Higginson L, Gladstone P, et al, the CCAIT Study Group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68.
36. Schuler G, Hanbrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet effects on progression of coronary artery disease. Circulation 1992;86:1-11.
37. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990;82:1940-53.
38. Moise A, Theroux P, Taeymans Y, et al. Clinical and angiographic factors associated with progression of coronary artery disease. J Am Coll Cardiol 1984;3:659-67.
39. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87:1067-75.
40. Byar DP, Piantadosi S. Factorial designs for randomized clinical trials. Natl Cancer Treat Rep 1985;69:1055-63.
41. Brittain E, Wittes J. Factorial designs in clinical trials: the effects of non-compliance and subadditivity. Stat Med 1989;8:161-71.
42. Jost S, Rafflenbeul W, Reil GH, et al. Elimination of variable vasomotor tone in studies with repeated quantitative coronary angiography. Int J Card Imaging 1990;5:125-34.
43. Ellis S, Sanders W, Goulere J. Optimal detection of the progression of coronary artery disease. Comparison of methods suitable for risk factor intervention trials. Circulation 1986;74:1235-42.
44. Selzer RH, Hagerly C, Azen SP, et al. Precision and reproducibility of quantitative coronary angiography with applications to controlled clinical trials. A sampling study. J Clin Invest 1989;83:520-6.
45. Reiber JHC, Serruys PW, Kooijman CJ, et al. Assessment of short-, medium- and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 1985;71:280-8.
46. Kornreich P, Rautaharju PM, Montague TJ. Identification of first acute Q wave and non-Q wave myocardial infarction by multivariate analysis of body surface potential maps. Circulation 1991;84:2442-53.
47. McPherson DD, Horacek BM, Sutherland DJ, Armstrong CS, Spencer CA, Montague TJ. Exercise ectrocardiographic mapping in normal subjects. J Electrocardiol 1985;18:351-60.
48. Montague TJ, Witkowski FX, Miller RM, et al. Exercise body surface mapping in single and multiple coronary artery disease. Chest 1990;97:1333-42.
49. Consensus Development Conference. Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080-6.
50. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
51. Bilheimer JW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983;80:4124-8.
52. Illingworth DR, Sexton GJ. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 1987;60:336-426.